Peptide News Digest

#Parabilis-Medicines

2 stories

Industry · View digest

Regeneron and Parabilis Medicines Announce $2.325B Antibody-Helicon Conjugate Collaboration (May 18) — $50M Upfront + $75M Equity + $2.2B Milestones Across Five Initial Targets

Regeneron Pharmaceuticals and Parabilis Medicines announced May 18 a strategic research collaboration to discover and develop antibody-Helicon conjugates (AHCs) — a novel modality combining Regeneron's antibody platform with Parabilis's Helicon stabilized helical peptide technology. Deal structure: $50M upfront, $75M equity commitment, and up to $2.2B in development and regulatory milestones across an initial five targets, plus tiered royalties. The Helicon platform locks peptides into their bioactive helical conformation, enabling targeting of historically undruggable protein-protein interaction surfaces that small molecules cannot access. The conjugate format pairs antibody-mediated tissue homing with peptide payload delivery — an extension of the broader peptide-drug-conjugate field that included Bicycle Therapeutics' bicyclic peptide-MMAE conjugates and Avacta's FAP-activated PDCs. The deal is the largest single peptide-platform partnership announced in 2026.

Industry · View digest

Parabilis Medicines Files S-1 for IPO (May 19): Helical-Peptide Zolucatetide Posts 74% Objective Response in 19-Patient Desmoid Cohort Ahead of Phase 3

Parabilis Medicines (formerly FogPharma) filed its S-1 on May 19 to list on Nasdaq under ticker PBLS, seeking ~$100M to fund Phase 3 of zolucatetide (FOG-001), a stabilized helical peptide and the first direct inhibitor of the β-catenin:TCF interaction. As of February 16, 38 desmoid-tumor patients were dosed; 25 had sufficient follow-up to be response-evaluable, all showed tumor reduction, and 74% of the 19 patients with ≥2 post-baseline scans hit RECIST 1.1 objective response. The IPO follows a $305M Series F in January and a Regeneron research deal worth up to $2B. FDA granted fast track designation for desmoid tumors.